Can we predict who's at risk for developing bone metastases in breast cancer?

Journal of Clinical Oncology

Volumn 29, Issue 27, 2011, Pages 3600-3604

  Korde, Larissa A ^a   Gralow, Julie R ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; BONE SIALOPROTEIN; CHEMOKINE RECEPTOR; CLODRONIC ACID; DENOSUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FAS LIGAND; IBANDRONIC ACID; INTERLEUKIN 8 RECEPTOR; OSTEOPONTIN; PARATHYROID HORMONE RECEPTOR; TAMOXIFEN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; BONE DENSITY; BONE METABOLISM; BONE METASTASIS; BONE REMODELING; BREAST CANCER; CANCER RISK; CANCER STAGING; CIRCULATING TUMOR CELL; CLINICAL TRIAL (TOPIC); DISSEMINATED CANCER; EDITORIAL; HUMAN; MITOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THORAX RADIOGRAPHY; URINALYSIS;

BIOLOGICAL MARKERS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; COLLAGEN TYPE I; FEMALE; HUMANS; PEPTIDES;

EID: 80053055375     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.7038     Document Type: Editorial

References (64)

1. Coleman RE: Skeletal complications of malignancy. Cancer 80:1588-1594, 1997
2. Orr FW, Varani J, Gondetz MD, et al: Chemotactic responses of tumor cells to products of resorbing bone. Science 203:176-179, 1979 (Pubitemid 9117878)
3. Diel IJ, Kaufmann M, Costa SD, et al: Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison to nodal status. J Natl Cancer Inst 88:1652-1658, 1996 (Pubitemid 26384811)
4. Mundy GR: Bone resorption and turnover in health and disease. Bone 8:S9-S16, 1987
5. Van der Pluijm G, Lowik C, Papapoulos S, et al: Tumor progression and angiogenesis in bone metastases from breast cancer: New approaches to an old problem. Cancer Treat Rev 26:11-27, 2000 (Pubitemid 30102798)
6. Powles T, Paterson A, McCloskey E, et al: Reduction of bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res 8:R13, 2006
7. Diel IJ, Jascke A, Solomayer EF, et al: Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow. Ann Oncol 19:2007-2011, 2008
8. Saarto T, Vehmanen L, Virkkunen P, et al: Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 43:650-656, 2004 (Pubitemid 39563937)
9. Coleman RE, Thorpe HC, Cameron D, et al: Adjuvant treatment with zoledronic acid in stage II/III breast cancer: The AZURE trial (BIG 01/04)-SABCS 2010. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010 (abstr S4-5)
10. Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer, N Engl J Med 360:679-691, 2009
11. Brufsky A, Bundred N, Coleman R, et al: Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13:503-514, 2008 (Pubitemid 351872868)
12. Bidard FC, Vincent-Salomon A, Gomme S, et al: Disseminated tumor cells of breast cancer patients: A strong predictive factor for distant and local relapse. Clin Cancer Res 14:3306-3311, 2008
13. Braun S, Vogl FD, Naume B, et al: A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793-802, 2005 (Pubitemid 41215488)
14. Colleoni M, O'Neill A, Goldhirsch A, et al: Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol 18:3925-3935, 2000
15. Smid M, Wang Y, Zhang Y, et al: Subtypes of breast cancer show preferential site of relapse. Cancer Res 68:3108-3114, 2008
16. Diel IJ: Prognostic factors for skeletal relapse in breast cancer. Cancer Treat Rev 27:153-157, 2001
17. Muller A, Homey B, Soto H, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50-56, 2001 (Pubitemid 32225831)
18. Henderson MA, Danks JA, Slavin JL, et al: Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. Cancer Res 66:2250-2256, 2006
19. Guise TA: Parathyroid hormone-related protein and bone metastases. Cancer 80:1572-1580, 1997
20. Bundred NJ, Walker RA, Ratcliffe WA, et al: Parathyroid hormone related protein and skeletal morbidity in breast cancer. Eur J Cancer 28:690-692, 1992
21. Powell GJ, Southby J, Danks JA, et al: Localization of parathyroid hormonerelated protein in breast cancer metastases: Increased incidence in bone compared with other sites. Cancer Res 51:3059-3061, 1991
22. Hoey RP, Anderson NG: The parathyroid hormone related protein receptor is expressed in breast cancer bone metastases and promotes autocrine proliferation in breast carcinoma cells. Br J Cancer 88:567-573, 2003 (Pubitemid 36363366)
23. Bellahcene A, Castronovo V: Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 146:95-100, 1995
24. Bendre MS, Gaddy-Kurten D, Mon-Foote T, et al: Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastases in vivo. Cancer Res 62:5571-5579, 2002
25. Andre F, Xia W, Conforti R, et al: CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist 14:1182-1188, 2009
26. Smith MC, Luker KE, Garbow JR: CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 64:8604-8612, 2004 (Pubitemid 39552073)
27. Clezardin P: Integrins in bone metastasis formation and potential therapeutic implications. Curr Cancer Drug Targets 9:801-806, 2009
28. Schneider JG, Amend SR, Weilbaecher KN: Integrins and bone metastasis: Integrating tumor cell and stromal cell interactions. Bone 48:54-65, 2011
29. Bebenek M, Dus D, Kozlak J: Fas/Fas-ligand expressions in primary breast cancer are significant predictors of its skeletal spread. Anticancer Res 27:215- 218, 2007
30. Jones DH, Nakashima T, Sanchez OH, et al: Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440:692-696, 2006
31. Schramek D, Leibbrandt A, Sigl V, et al: Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468:98-102, 2010
32. Gonzalez-Suarez E, Jacob AP, Jones J, et al: RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468:103-107, 2010
33. Smid M, Wang Y, Klijn JG, et al: Genes associated with breast cancer metastatic to bone. J Clin Oncol 24:2261-2267, 2006 (Pubitemid 46630655)
34. Kang Y, Siegel PM, Shu W, et al: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537-549, 2003 (Pubitemid 36808649)
35. Minn AJ, Kang Y, Serganova I, et al: Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 115:44-55, 2005 (Pubitemid 40385504)
36. Fohr B, Dunstan CR, Seibel MJ: Clinical review 165: markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab 88:5059-5075, 2003 (Pubitemid 37452696)
37. Vasikaran S, Eastell R, Bruyere O, et al: Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: A need for international reference standards. Osteoporosis Int 22:391-420, 2011
38. Huang Q, Ouyang X: Biochemical-markers for the diagnosis of bone metastasis: A review in clinical. Cancer Epidemiol [epub ahead of print on April 5, 2011]
39. Leeming DJ, Koizumi M, Byrjalsen I, et al: The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate or lung cancer patients. Cancer Epidemiol Biomarkers Prev 15:32-38, 2006
40. Coleman R, Costa L, Saad F, et al: Consensus on the utility of bone markers in the malignant bone disease setting. Crit Rev Oncol Hematol [epub ahead of print on March 14, 2011]
41. Costa L, Demers LM, Gouveia-Oliveira A, e al: Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 20:850-856, 2002
42. Bjarnason NH, Henriksen EE, Alexandersen P, et al: Mechanism of circadian variation in bone resorption. Bone 30:307-313, 2002 (Pubitemid 34044332)
43. Diel IJ, Solomayer EF, Seibel MJ, et al: Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 5:3914-3919, 1999 (Pubitemid 30013765)
44. Lipton A, Chapman J-W, Demers L, et al: Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: NCIC CTG MA.14. J Clin Oncol 29:3605-3610, 2011
45. Pollak MN, Chapman JW, Pritchard KI, et al: NCIC-CTG MA14 trial: Tamoxifen (tam) vs. tam + octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast cancer. J Clin Oncol 26:14s, 2008 (suppl; abstr 532)
46. Saarto T, Vehmanen L, Blomqvist C, et al: Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. J Clin Oncol 26:4289-4295, 2008
47. Saarto T, Blomqvist C, Valimaki M, et al: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341-1347, 1997 (Pubitemid 27167365)
48. Ellis GK, Bone HG, Chlebowski R, et al: Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26:4875-4882, 2008
49. Lester JE, Dodwell D, Purohit OP, et al: Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14:6336-6342, 2008
50. Van Poznak C, Hannon RA, Mackey JR, et al: Prevention of aromatase inhibitor-induced bone loss using risedronate: The SABRE trial. J Clin Oncol 28:967-975, 2010
51. Delmas PD, Balena R, Confravreux E, et al: Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study. J Clin Oncol 15:955-962, 1997 (Pubitemid 27106277)
52. Ripps BA, VanGilder K, Minhas B, et al: Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy. J Reprod Med 48:761-766, 2003 (Pubitemid 37314941)
53. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al: Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25:820-828, 2007 (Pubitemid 350002882)
54. Brufsky AM, Bosserman LD, Caradonna RR, et al: Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9:77-85, 2009
55. Eidtmann H, De Boer R, Bundred N, et al: Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 21:2188-2194, 2010
56. Paterson AH, Powles TJ, Kanis JA, et al: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65, 1993 (Pubitemid 23059975)
57. Body JJ, Diel IJ, Lichinitzer M, et al: Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo-controlled phase III studies. Br J Cancer 90:1133-1137, 2004 (Pubitemid 38496803)
58. Body JJ, Diel IJ, Lichinitser MR, et al: Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399-1405, 2003 (Pubitemid 37185286)
59. Lipton A, Theriault RL, Hortobagyi GN, et al: Pamidronate prevents skeletal complications and is effective treatment in women with breast carcinoma and osteolytic bone metastases. Cancer 88:1082-1090, 2000
60. Rosen LS, Gordon D, Antonio BS, et al: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 7:377-387, 2001 (Pubitemid 33759002)
61. Stopeck AT, Lipton A, Body JJ, et al: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double blind study. J Clin Oncol 28:5132-5139, 2010
62. Costa L, Harper P, Coleman RE, et al: Anticancer evidence for zoledronic acid across the cancer continuum. Crit Rev Oncol Hematol 77:S31-37, 2011
63. Gnant M, Mlineritsch H, Stoeger H, et al: Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: Long-term results from ABCSG-12. J Clin Oncol 29:50s, 2011 (suppl; abstr 520)
64. Gralow JR, Biermann JS, Farooki A, et al: NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw 7:S1-S32, 2009